



Identification of highly-protective combinations of *Plasmodium vivax* recombinant proteins for vaccine development

Camila Tenorio França^{1,2}, Michael T White^{1,3}, Wen-Qiang He^{2,4}, Jessica B Hostetler^{5,6}, Jessica Brewster⁴, Gabriel Frato⁷, Indu Malhotra⁷, Jakub Gruszczyk⁴, Christele Huon⁸, Enmoore Lin⁹, Benson Kiniboro⁹, Anjali Yadava¹⁰, Peter Siba⁹, Mary R Galinski^{11,12}, Julie Healer^{2,4}, Chetan Chitnis^{8,13}, Alan F Cowman^{2,4}, Eizo Takashima¹⁰, Takafumi Tsuboi¹⁴, Wai-Hong Tham^{2,4}, Rick M Fairhurst⁶, Julian C Rayner⁵, Christopher L King⁷, Ivo Mueller^{1,2,15,16*}

¹Division of Population Health and Immunity, Walter and Eliza Hall Institute, Parkville, Australia; ²Department of Medical Biology, University of Melbourne, Parkville, Australia; ³MRC Center for Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology, Imperial College London, London, United Kingdom; ⁴Division of Infection and Immunity, Walter and Eliza Hall Institute, Parkville, Australia; ⁵Malaria Programme, Wellcome Trust Sanger Institute, Hinxton, United Kingdom; ⁶Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, United States; ⁷Center for Global Health and Diseases, Case Western Reserve University, Cleveland, United States; ⁸Malaria Parasite Biology and Vaccines Unit, Institut Pasteur, Paris, France; ⁹Malaria Immuno-Epidemiology Unit, PNG Institute of Medical Research, Yagaum, Papua New Guinea; ¹⁰Malaria Vaccine Branch, Walter Reed Army Institute of Research, Silver Spring, United States; ¹¹International Center for Malaria Research, Education, and Development, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, United States; ¹²Infectious Diseases Division, Department of Medicine, Emory University, Atlanta, United States; ¹³International Centre for Genetic Engineering and Biotechnology, New Delhi, India; ¹⁴Division of Malaria Research, Proteo-Science Center, Ehime University, Matsuyama, Japan; ¹⁵Malaria Parasites and Hosts Unit, Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France; ¹⁶Barcelona Institute of Global Health, Barcelona, Spain

*For correspondence:
mueller@wehi.edu.au

Competing interests: The authors declare that no competing interests exist.

Funding: See page 16

Received: 16 May 2017

Accepted: 25 September 2017

Published: 26 September 2017

Reviewing editor: Urszula Krzych, Walter Reed Army Institute of Research, United States

© Copyright França et al. This article is distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use and redistribution provided that the original author and source are credited.

Abstract The study of antigenic targets of naturally-acquired immunity is essential to identify and prioritize antigens for further functional characterization. We measured total IgG antibodies to 38 *P. vivax* antigens, investigating their relationship with prospective risk of malaria in a cohort of 1–3 years old Papua New Guinean children. Using simulated annealing algorithms, the potential protective efficacy of antibodies to multiple antigen-combinations, and the antibody thresholds associated with protection were investigated for the first time. High antibody levels to multiple known and newly identified proteins were strongly associated with protection (IRR 0.44–0.74, $p < 0.001$ – 0.041). Among five-antigen combinations with the strongest protective effect (>90%), EBP, DBPII, RBP1a, CyRPA, and PVX_081550 were most frequently identified; several of them

requiring very low antibody levels to show a protective association. These data identify individual antigens that should be prioritized for further functional testing and establish a clear path to testing a multicomponent *P. vivax* vaccine.

DOI: <https://doi.org/10.7554/eLife.28673.001>

Introduction

Plasmodium vivax is the predominant species causing malaria in the Americas and Asia-Pacific regions (WHO, 2014). Due to its unique biology, *P. vivax* is less susceptible to commonly-used vector control measures (Mueller et al., 2009). With renewed funding and commitment towards the goal of eliminating malaria, the development and deployment of an effective vaccine against *P. vivax* has become a high priority (malERA Consultative Group on Vaccines, 2011).

The epidemiology of *P. vivax* provides strong indication that the development of an effective vaccine is feasible. Clinical immunity to *P. vivax* is acquired more rapidly than to *P. falciparum* and, in moderate and highly endemic areas, clinical disease is virtually absent in children older than five years (Phimpraphi et al., 2008; Lin et al., 2010; Robinson et al., 2015). Sub-microscopic infections are common even in areas where malaria transmission has been substantially reduced (Cheng et al., 2015; Bousema et al., 2014), suggesting the development of effective immunity that provides good control of parasitemia. Whilst our understanding of the protective immune effector mechanisms is incomplete, the humoral component is thought to be essential for the development of anti-*P. vivax* immunity, and antibodies confer protection by both preventing high-density parasitemia and inhibiting blood-stage replication (Longley et al., 2016). Evidence of relatively long-lived IgG levels and/or seropositivity to *P. vivax* proteins such as circumsporozoite protein (CSP), merozoite surface protein 1 (MSP1), apical membrane antigen 1 (AMA1) and Duffy binding protein (DBP) have been reported even in the absence of detectable *P. vivax* infections (Longley et al., 2015; Wipasa et al., 2010; Achtman et al., 2005).

A highly-efficacious malaria vaccine has unfortunately not yet been achieved for any of the *Plasmodium* spp. parasites, and the vast majority of vaccines in development are based on single recombinant protein antigens (Halbroth and Draper, 2015). For *P. falciparum*, more than 15 antigens are under pre-clinical or clinical testing, including the pre-erythrocytic, CSP-based RTS,S/AS01 vaccine, which has recently completed Phase 3 trials (Agnandji et al., 2012; RTS,S Clinical Trials Partnership, 2014). In contrast, for *P. vivax* only a handful of proteins have been studied, with the blood-stage DBP, MSP1, and transmission-blocking protein Pvs25 as the main vaccine candidates (Halbroth and Draper, 2015; Mueller et al., 2015). The moderate success of the *P. falciparum* RTS,S vaccine has also made *P. vivax* CSP a main vaccine candidate (Mueller et al., 2015; Salman et al., 2017; Bennett et al., 2016). The potential of novel, pre-erythrocytic candidate antigens, including *P. vivax* cell-traversal protein for ookinetes (CelTOS) and thrombospondin-related anonymous protein (TRAP) is being investigated in animal models (Mueller et al., 2015; Alves et al., 2017; Bauza et al., 2014).

Recent serological screens of large panels of *P. falciparum* proteins in naturally-exposed populations have identified several antigenic targets associated with protective immunity, and strongly support the hypothesis that a multicomponent vaccine possibly including antigens from different stages of the parasites life cycle would offer a higher degree of protection than a single component vaccine (Halbroth and Draper, 2015; Richards et al., 2013; Osier et al., 2014a). For *P. vivax*, the availability of the genome sequence (Carlton et al., 2008) and transcriptome (Bozdech et al., 2008) have enhanced our understanding of the parasite's biology, facilitating the identification of many proteins that are homologous to *P. falciparum* antigens (Chen et al., 2010; Lu et al., 2014; Finney et al., 2014). Given the lack of methods to continuously culture *P. vivax* to study specific proteins in vitro, or animal models for extensive in vivo assays, the study of targets of human natural immunity in exposed populations must play an essential role in identifying and prioritizing *P. vivax* antigens for further functional characterization for vaccine or biomarker development (Chia et al., 2014). To date, however, the number, identity, and relative importance of *P. vivax* antigenic targets remains poorly explored (Cutts et al., 2014). Antibodies to proteins such as MSP3 α , MSP9 (30) and DBP (King et al., 2008; Cole-Tobian et al., 2009) have shown strong associations with reduced risk of

clinical disease or blood-stage infection. Screening studies to extend the pool of *P. vivax* vaccine candidates remain scarce (Cutts et al., 2014).

To explore the reservoir of antigenic targets and prioritize candidates for functional characterization, we investigated the association between IgG to a comprehensive library of 38 *P. vivax* recombinant antigens and risk of vivax malaria in a cohort of young Papua New Guinean (PNG) children with well-characterized differences in exposure to *P. vivax* infections (Lin et al., 2010). To our knowledge, the potential existence of synergistic or additive effects of combinations of antibody responses to a large panel of *P. vivax* antigens has never been explored. We applied a novel simulated annealing algorithm to efficiently explore the vast space of antigen combinations and thus identify combinations with optimal potential protective efficacy (PPE). High antibody levels to multiple antigens, including several novel proteins were strongly associated with reduced risk of vivax malaria, independently of individual differences in exposure, age, and transmission season. Combinations of antigens were identified with a PPE of >90%. These data identify several antigens that should be prioritized for further functional characterization. The naturally-acquired anti-malarial immunity explored in this study supports the development of a highly-efficacious, multicomponent *P. vivax* vaccine.

Results

Breadth of anti-*P. vivax* IgG antibodies in young PNG children

We selected 38 *P. vivax* antigens that are predominantly expressed at the late-schizont stage and have a potential role in erythrocyte binding or invasion. A complete description of antigens and their accession numbers can be found in **Supplementary file 1**. Antigens were expressed using mostly the wheat germ cell free (WGCF) system, human embryonic kidney (HEK) 293E cells, and *Escherichia coli* (Tsuboi et al., 2010; Hostetler et al., 2015; Gruszczuk et al., 2016). Most were individual, little-studied antigens, but in the case of the major vaccine candidate DBP11, several alleles were included as antibody responses have been shown to be strain specific (Cole-Tobian et al., 2009). In addition, for one antigen (MSP3 α), we included both conserved (N and C terminals) and polymorphic (block 1 and block 2) sub-domains (Rayner et al., 2002), as the different regions have been shown to differ in their immunogenicity and association with protective immunity (Stanisic et al., 2013).

Although children were reactive to all 38 proteins tested, antibody seroprevalence varied largely (Table 1). Whereas more than 56% of children had already acquired antibody levels to Pv-fam-a/PVX_088820 that were above 10% of the levels observed in pooled serum from PNG adults (considered to be the 'steady-state equilibrium' levels achievable under natural exposure [França et al., 2016a]), none of the children had achieved antibody levels above this threshold to antigens such as GAMA, PVX_081550, or P12 (median = 12.7%, interquartile range [IQR] 3.5–31.7; Table 1).

To study the breadth of anti-*P. vivax* antibodies, for each antigen, antibody levels were stratified into tertiles and scored as 0, 1 and 2 for the low, medium and high tertiles, respectively. Scores were then summed to yield a median score of 37 (IQR 20–55), and fitted as a continuous variable in a negative binomial generalized estimating equation (GEE) model. Antibody repertoire increased only moderately with increasing age, with the most marked increases occurring during the first two years of life ($p=0.049$) (Figure 1a).

Given the young age and large heterogeneity in exposure among children, however, age alone is not the best proxy for lifetime exposure to malaria (Lin et al., 2010; Koepfli et al., 2013). All *P. vivax* infections occurred during the follow-up of this cohort have been genotyped, and the molecular force of blood-stage infections (molFOB, i.e. the number of genetically distinct blood-stage infections acquired over time) calculated. The molFOB is therefore a direct measure of individual differences in exposure to *P. vivax* infections (Koepfli et al., 2013), and has demonstrated strong correlation with factors associated with increased exposure to malaria parasites such as seasonality, geographical location, and use of bed nets; and has been shown to be the major predictor of clinical disease in this cohort of children (Koepfli et al., 2013; Mueller et al., 2012). Hence, the product of molFOB and age represents a more precise estimation of lifetime exposure to *P. vivax*. As expected, children with the highest lifetime exposure to *P. vivax* infections were able to recognize a higher number of proteins ($p=0.030$ – 0.001) (Figure 1b). Children currently infected (detected by PCR) were

Table 1. Seroprevalence of antibodies to 38 *P. vivax* proteins in Papua New Guinean children aged 1–3 years.

Location	Protein	Geom mean*	95% CI*	No. of children (%)				
				1% of adult levels	5% of adult levels	10% of adult levels	25% of adult levels	50% of adult levels
GPI-anchored merozoite surface	MSP1 19	0.47	0.38 0.57	152 (67.9)	67 (29.9)	38 (17.0)	21 (9.4)	13 (5.8)
	P12	0.02	0.02 0.03	33 (14.7)	2 (0.9)	0	0	0
Peripheral surface	MSP3a full	1.17	1.05 1.31	222 (99.1)	121 (54.0)	51 (22.8)	12 (5.4)	3 (1.3)
	MSP3a block 1	0.79	0.72 0.86	222 (99.1)	82 (36.6)	18 (8.0)	3 (1.3)	0
	MSP3a block 2	0.54	0.48 0.60	202 (90.2)	48 (21.4)	13 (5.8)	4 (1.8)	1 (0.4)
	MSP3a N-term	0.11	0.10 0.13	222 (99.1)	139 (62.0)	64 (28.6)	11 (4.9)	4 (1.8)
	MSP3a C-term	0.11	0.10 0.13	62 (27.7)	4 (1.8)	1 (0.4)	0	0
	MSP9 N-term	0.09	0.08 0.11	62 (27.7)	7 (3.1)	3 (1.3)	0	0
	P41	0.02	0.02 0.02	20 (8.9)	8 (3.6)	3 (1.3)	0	0
	SERA	0.96	0.87 1.07	224 (99.6)	93 (41.4)	38 (16.9)	8 (3.6)	3 (1.3)
Microneme	AMA1	0.41	0.36 0.47	167 (74.6)	34 (15.2)	19 (8.5)	5 (2.2)	1 (0.4)
	DBP1I Sal1	0.24	0.21 0.27	127 (56.7)	17 (7.6)	9 (4.0)	3 (1.3)	2 (0.9)
	DBP1I P	0.23	0.19 0.28	125 (55.8)	26 (11.6)	12 (5.4)	3 (1.3)	3 (1.3)
	DBP1I O	0.34	0.28 0.40	146 (65.2)	38 (17.0)	13 (5.8)	5 (2.2)	3 (1.3)
	DBP1I AH	0.24	0.21 0.27	128 (57.1)	15 (6.7)	7 (3.1)	2 (0.9)	2 (0.9)
	DBP1I C	0.23	0.19 0.27	125 (55.8)	26 (11.6)	11 (4.9)	3 (1.3)	3 (1.3)
	EBP	0.40	0.33 0.48	142 (63.1)	60 (26.7)	36 (16.0)	14 (6.2)	6 (2.7)
	GAMA	0.01	0.01 0.01	5 (2.2)	1 (0.4)	0	0	0
	CyRPA	0.54	0.42 0.69	139 (61.8)	78 (34.7)	54 (24.0)	40 (17.8)	31 (13.8)
Rhoptry	ARP	0.40	0.37 0.43	205 (91.1)	17 (7.6)	6 (2.7)	0	0
	RBP1a	0.41	0.35 0.47	162 (72.3)	39 (17.4)	18 (8.0)	9 (4.0)	3 (1.3)
	RBP2a	0.86	0.72 1.04	186 (83.0)	102 (45.5)	64 (28.6)	29 (12.9)	13 (5.8)
	RBP2b	1.19	1.02 1.38	209 (93.3)	130 (58.0)	90 (40.2)	12 (5.4)	3 (1.3)
	RBP2cNB	0.40	0.34 0.47	159 (71.0)	40 (17.9)	29 (12.9)	13 (5.8)	8 (3.6)
	RBP2-P2	1.68	1.49 1.91	224 (100.0)	156 (69.6)	89 (39.7)	24 (10.7)	13 (5.8)
	RhopH2	1.40	1.26 1.57	224 (99.6)	144 (64.0)	72 (32.0)	18 (8.0)	3 (1.3)
	RAMA	1.44	1.30 1.61	225 (100.0)	146 (64.9)	61 (27.1)	20 (8.9)	7 (3.1)
Pre-erythrocytic	CSP	0.15	0.12 0.18	95 (42.4)	21 (9.4)	8 (3.6)	2 (0.9)	1 (0.4)
	PVX_080665	0.68	0.61 0.76	214 (95.5)	59 (26.3)	28 (12.5)	4 (1.8)	1 (0.4)
Other	PVX_081550	0.03	0.03 0.04	6 (2.7)	0	0	0	0
	PVX_094350	1.44	1.30 1.59	225 (100.0)	148 (65.8)	65 (28.9)	15 (6.7)	6 (2.7)
	AKLP2	1.35	1.20 1.52	225 (100.0)	134 (59.6)	71 (31.6)	17 (7.6)	7 (3.1)
	PVX_087670	1.71	1.54 1.89	225 (100.0)	160 (71.1)	80 (35.6)	22 (9.8)	7 (3.1)
	PVX_122805	2.04	1.85 2.24	225 (100.0)	189 (84.0)	108 (48.0)	24 (10.7)	6 (2.7)
	CCp5	1.69	1.52 1.88	225 (100.0)	162 (72.0)	79 (35.1)	20 (8.9)	9 (4.0)
	PVX_114330	2.16	1.98 2.37	225 (100.0)	198 (88.0)	120 (53.3)	28 (12.4)	4 (1.8)
	Pv-fam-a/ PVX_088820	2.38	2.17 2.60	225 (100.0)	209 (92.9)	127 (56.4)	32 (14.2)	6 (2.7)
	Pv-fam-a/ PVX_092995	1.85	1.70 2.02	225 (100.0)	184 (81.8)	93 (41.3)	18 (8.0)	5 (2.2)

Abbreviations: No = number; Geom mean = geometric mean; 95% CI = 95% confidence interval. *IgG levels multiplied by 1000. Values are in relative antibody units interpolated from standard curves using a 5PL logistic regression model.

DOI: <https://doi.org/10.7554/eLife.28673.002>




Figure 1. Breadth of IgG antibodies to 38 *P. vivax* proteins in Papua New Guinean children aged 1–3 years. For each protein, antibody levels were stratified into tertiles and scored as 0, 1 or 2 for the low, medium, and high tertiles, respectively. Scores were then added up to reflect the breadth of antibodies per child. (a) Antibody breadth by age group. Age is shown as median (interquartile range). (b) Antibody breadth by lifetime exposure group. For each child, exposure was defined as the total number of *P. vivax* blood-stage clones acquired per time-at-risk (molFOB), and lifetime exposure as a product of age and molFOB. P values are from negative binomial regression and were deemed significant if <0.05 .

DOI: <https://doi.org/10.7554/eLife.28673.003>

also able to recognize more proteins (median breadth score = 43, IQR 26–60) than those that were infection-free at the time of sampling (median = 31, IQR 12–45, $p < 0.001$).

Exposure-related changes in magnitude of IgG levels

The overall antibody levels (i.e. the sum of antibodies to all proteins per child) also increased moderately with age (Pearson correlation coefficient = 0.15, $p = 0.019$) (Figure 2a). Increases in antibody levels with age were observed for 22 individual antigens (Spearman's rho = 0.14–0.28, $P < 0.001$ –0.031) (Figure 2a; Figure 2—source data 1). Our proxy for lifetime exposure was a substantially better predictor of antibody levels than age, and overall IgG levels increased more strongly with lifetime exposure (Pearson correlation coefficient = 0.24, $p < 0.001$) (Figure 2b). IgG to 29 individual proteins increased with lifetime exposure (rho = 0.14–0.38, $p < 0.001$ –0.040), the majority of them more strongly in children with a current *P. vivax* infection (rho = 0.20–0.43, $P < 0.001$ –0.048) (Figure 2b; Figure 2—source data 1).

IgG levels and prospective risk of vivax malaria

Over 16 months of follow-up, the subset of children included in this study experienced an incidence rate of 1.25 (95%CI 1.08–1.45) clinical episodes defined as fever or history of fever in the last 48 hr with concurrent *P. vivax* parasitemia $>500/\mu\text{L}$. After adjusting our GEE model for age, season, village of residency, and individual differences in exposure as measured by molFOB (Koepli et al., 2013), high antibody levels to 31 of the 38 antigens tested (81.6%) were associated with reduced risk of vivax malaria (incidence rate ratio [IRR] high versus low tertiles of responders 0.44–0.70, $p < 0.001$ –0.035) (Figure 3; Figure 3—source data 1). When antigen-specific responses were ranked according to the strength of their protective associations, except for MSP3 α , all other antigens in the top-10 were either novel or understudied proteins, including EBP, PVX_081550, PVX_122805, CyRPA, RBP1a, RBP2b and P41 (Figure 3).

In unadjusted analysis, children with medium and/or high IgG levels to several *P. vivax* antigens showed an increased risk of falciparum malaria with density <2500 parasites/ μL (IRR 1.24–1.50, $p = 0.001$ –0.045; Figure 3—source data 2), suggesting that in this age group antibodies to *P. vivax* are also markers of a higher co-exposure to *P. falciparum* infections, and thus increased risk of




Figure 2. Association between cumulative IgG levels to 38 *P. vivax* proteins and exposure to *P. vivax* infections in Papua New Guinean children aged 1–3 years. (a) Association with age. (b) Association with lifetime exposure. For each child, exposure was defined as the total number of *P. vivax* blood-stage clones acquired per time-at-risk (molFOB), and lifetime exposure as a product of age and molFOB. $n = 225$. P values < 0.05 were deemed significant.

DOI: <https://doi.org/10.7554/eLife.28673.004>

The following source data is available for figure 2:

Source data 1. Associations between IgG to *P. vivax* antigens with measures of concurrent and cumulative exposure in Papua New Guinean children aged 1–3 years.

DOI: <https://doi.org/10.7554/eLife.28673.005>

developing falciparum malaria (Mueller et al., 2012). After adjusting for covariates, antibodies to none of the *P. vivax* antigens were associated with reduced risk of falciparum malaria (with any parasite density), suggesting that the protection observed for *P. vivax* is species-specific (Figure 3; Figure 3—source data 1 and 2).

Co-acquisition and cross-reactivity of IgG levels to different proteins

Antibody responses to the 38 different antigens were, however, significantly correlated ($\rho = 0.14$ – 0.995 , $p < 0.05$) (Figure 4). The strongest correlations were among antibodies to the different alleles of DBP11 ($\rho = 0.76$ – 0.995 , $p < 0.001$) (Figure 4). DBP11 shares 50% identity with EBP, and correlations between antibodies to the different alleles of DBP11 and EBP were moderate ($\rho = 0.36$ – 0.48 , $p < 0.001$) (Figure 4). Antibody levels to the different RBPs ($\rho = 0.51$ – 0.70 , $p < 0.001$) and to different regions of MSP3 α were also highly correlated ($\rho = 0.52$ – 0.93 , $p < 0.001$). Among the other proteins, antibodies to the WGCF-expressed, highly-immunogenic proteins generally showed very high correlations ($\rho = 0.61$ – 0.95 , $p < 0.001$), while antibodies to the HEK293E-expressed, full-ectodomain proteins showed lower correlations ($\rho = 0.15$ – 0.66 , $P < 0.001$ – 0.035), both among themselves and to other proteins (Figure 4).

Potential protective efficacy of IgG antibodies to protein combinations

The complex and strongly-correlated nature of naturally-acquired antibodies makes prioritizing individual proteins based solely on the strength of their respective associations with malaria risk disease extremely difficult. We therefore investigated the effect of responses to combinations of proteins on the risk of vivax malaria, based on the premise that a combination of responses is likely to be more efficacious than a response to a single component, given the complexity of *P. vivax* biology and the (co-) acquisition of humoral immunity to this parasite. For this we applied a novel simulated annealing algorithm to efficiently explore the vast space of antigen combinations, examining the potential protective efficacy (PPE) of combining antibodies to 5–38 antigens on the association with risk of disease.

Association with protection from clinical malaria increased with increasing the number of antigens, but at a diminishing rate (Figure 5a and b). The PPE increased from $< 75\%$ for individual antigens to $> 90\%$ for combinations of antibodies to 5–38 proteins. Including antibody response to more than 20 proteins, however, did not lead to a significant further increase in PPE (Figure 5a and b).




Figure 3. Association between high IgG levels to 38 *P. vivax* proteins and protection against clinical malaria (density >500/ μ L) in Papua New Guinean children aged 1–3 years old. Data are plotted as incidence rate ratios and 95% confidence intervals adjusted for exposure (molFOB), age, season, and village of residency. Incidence rate ratios are for high versus low tertiles of responders, 95% confidence intervals and P values are from GEE models. P values < 0.05 were deemed significant.

DOI: <https://doi.org/10.7554/eLife.28673.006>

The following source data is available for figure 3:

Figure 3 continued on next page

Figure 3 continued

Source data 1. Associations between antibodies to 38 *P. vivax* proteins and risk of *P. vivax* clinical episodes (>500 parasites/ μ L) in Papua New Guinean children aged 1–3 years.

DOI: <https://doi.org/10.7554/eLife.28673.007>

Source data 2. Associations between antibodies to 38 *P. vivax* proteins and risk of *P. falciparum* clinical episodes (>2500 parasites/ μ L) in Papua New Guinean children aged 1–3 years.

DOI: <https://doi.org/10.7554/eLife.28673.008>

Synergistic or additive effects could also be restricted to specific combinations of proteins. The PPE of every possible combination of one to five, as well as 33 to 38 proteins was investigated, and optimal five-way combinations were identified that already showed >90% protective efficacy without addition of further proteins (**Figure 5a and b**). Antigens with higher individual protective efficacies were more likely to be included in any five-component, highly-efficacious combination (**Figure 5c**




Figure 4. Correlations between IgG to 38 *P. vivax* proteins in Papua New Guinean children aged 1–3 years. Correlation coefficients between antibody levels to every pair of antigens were calculated using Spearman’s rank correlation tests.

DOI: <https://doi.org/10.7554/eLife.28673.009>




Figure 5. Association between antibodies to combinations of *P. vivax* proteins and malaria risk in Papua New Guinean children aged 1–3 years. (a) Potential protective efficacy (PPE) for combinations of antigens with the maximum number of antigens indicated on the x-axis. Dashed lines represent the range of PPE for all possible combinations. Solid lines represent the range of PPE from 1000 implementations of the simulated annealing algorithm. (b) Sum of residuals (as a measure of model goodness of fit). (c) The heatmap shows the frequency of including an antigen (x-axis) in a multi-component. *Figure 5 continued on next page*

Figure 5 continued

vaccine with a fixed number of antigens (y-axis). (d) Predicted PPE of a single antigen. (e) Immunogenicity of each antigen represented as seroprevalence with a cut-off as 10% of the antibody levels of fully-immune PNG adults.

DOI: <https://doi.org/10.7554/eLife.28673.010>

and d). These included EBP, PVX_081550, P41, DBPII (variant O), RBP1a, and CyRPA, but not MSP3 α for example (**Figure 5c**). In combinations of more than five antigens, these antigens were also consistently selected (**Figure 5c**). There was no obvious evidence that the probability of inclusion was associated with higher immunogenicity of the antigen (**Figure 5e**). Among antigens with the lowest probability of being included in any combination with <35 antigens were both the highly-immunogenic PVX_114330 and the poorly-immunogenic ARP and GAMA (**Figure 5c and e**).

Thresholds of IgG levels and protection

Although it was not possible to give an absolute quantification of antigen-specific antibody concentration in this study, there was evidence of different antigen-specific dose-response patterns and association with reduced risk of vivax malaria. Using a mathematical dose-response model adjusted for exposure (molFOB), predicted threshold ranges (relative to the PNG immune adult pool) at which antibodies become associated with protection were observed for the different antigens (**Figure 6; Figure 6—figure supplement 1**).

The dose-response model predicts that among all antigens, MSP3 α C-term and MSP9 N-term need the lowest levels of specific antibodies to show an association with 50% reduction in symptomatic infections, followed by CyRPA, EBP, RBP1a, RBP2b, and RBP2-P2 (**Figure 6a–c; Figure 6—figure supplement 1**). Intermediate antibody levels were predicted for the full-ectodomain and other regions of MSP3 α , as well as several of the bioinformatically-selected proteins, including CCp5, AKLP2, and PVX_087670 among others (**Figure 6d–f; Figure 6—figure supplement 1**). Whereas the different DBPII alleles have intermediate profiles, increasing levels of antibodies to the P, C, and O variants of DBPII were associated with a gradual reduction in the incidence of clinical disease (**Figure 6—figure supplement 1**). A 50% ‘protective’ effect, however, would need very high antibody levels for antigens such as Pv-fam-a/PVX_088820, SERA and PVX_114330, or may never be achieved with increasing antibody levels to RBP2a, MSP1 19, and others (**Figure 6g–i; Figure 6—figure supplement 1**).

In order to assure the observed results were not influenced by the concentration of the antigen conjugated onto the assay beads, we correlated the antigen concentration with the geometric mean antibody levels observed in children, the levels at which 50% protection is achieved (if it is achieved at all), and the maximum level of protection achieved. For none of these variables a significant correlation was observed ($\rho = -0.16$ to 0.20 , $p > 0.3$), indicating that the conjugated antigen concentrations did not influence the relationship between antibody levels and the level protection achieved (**Figure 6—source data 1**).

Discussion

The development and deployment of an effective *P. vivax* vaccine has become a priority for accelerating malaria elimination in the Asia-Pacific and the Americas (**Tanner et al., 2015**). To date, however, remarkably few *P. vivax* vaccine candidates are close to or have reached clinical trials (**Mueller et al., 2015**). To expand and prioritize the reservoir of antigenic targets for further functional characterization for use in vaccine or biomarker development, we measured total IgG antibody levels to 38 *P. vivax* recombinant proteins, investigating their relationship with prospective risk of vivax malaria in a longitudinal cohort of PNG children aged 1–3 years. For the first time, the potential protective efficacy of combination of antigens, and the thresholds necessary for an association with protection were investigated.

Although the young children included in the present study are actively acquiring clinical immunity, as indicated by a highly-significant decrease in incidence of clinical *P. vivax* episodes (**Lin et al., 2010**), most still had relatively low antibody responses, with more than 10% of children exceeding 10% of adult levels to only 22 proteins. Antibodies to almost all proteins were boosted by




Figure 6. Estimated dose-response curves for the associations between antibody responses specific to *P. vivax* antigens and protection from clinical malaria. Solid black lines depict exposure-adjusted dose-response curves, and the grey shaded regions depict the 95% credible intervals. Histograms show the observed distribution of antibody levels (relative to the PNG immune pool) colored per tertiles (low = blue; medium = green; high = red), and the darkly-colored portions of the histograms show the proportion of individuals with that antibody level who had a *P. vivax* episode (>500 parasites/ μ L). (a–c) Examples of antigens that need low antibody levels to provide 50% of protection. (d–f) Examples of antigens that need medium antibody levels to provide 50% of protection. (g–i) Examples of antigens that need high antibody levels to provide 50% of protection.

DOI: <https://doi.org/10.7554/eLife.28673.011>

The following source data and figure supplement are available for figure 6:

Source data 1. Antibody levels and 50% protection from clinical malaria.

DOI: <https://doi.org/10.7554/eLife.28673.013>

Figure supplement 1. Estimated dose-response curves for the associations between antibody levels to *P. vivax* antigens and protection from clinical malaria.

DOI: <https://doi.org/10.7554/eLife.28673.012>

concurrent *P. vivax* infections ($n = 30$), and 29 increased with age and/or lifetime exposure, indicating the antibody levels are both a marker of concurrent and past exposure to *P. vivax*. Despite these generally low IgG antibody levels, high levels to 31 of 38 proteins (81.6%) were significantly associated with protection, indicating that these antibody levels have started to exceed the threshold above which antibody levels are biomarkers of protection rather than exposure (Stanisic et al., 2015).

Antibody levels were often moderately or even highly correlated between antigens, and not only to different regions of the same antigen, such as MSP3 α ($\rho = 0.52$ – 0.93), or to different alleles of the same antigen such as PvDBP ($\rho = 0.76$ – 0.995). In particular, antibodies to the WGCF-expressed, highly-immunogenic proteins showed very high correlations ($\rho = 0.61$ – 0.95). Without further functional investigation, it is difficult to determine if these correlations indicate co-acquisition or cross-reactivity, or whether cross-reactive antibodies are functional or merely recognize different proteins.

The high correlations of antibody levels to different DBP alleles were expected, as some are very similar in sequence (e.g. the variants AH and C differ only at amino acid residue 371), thus antibody responses are likely to be highly cross-reactive between variants. However, despite 50% identity, correlations between antibodies to the different alleles of DBP11 and EBP were only moderate ($\rho = 0.36$ – 0.48 , $p < 0.001$) and not higher than those with other merozoite surface proteins, indicating only a limited potential for cross-reactive antibodies between these proteins. For the RBP proteins included in this study, we have previously showed that polyclonal antibodies raised in rabbits recognize the homologous but not heterologous proteins (França *et al.*, 2016b). The correlated responses are therefore likely due to co-acquisition, and the combination of several RBPs may have synergistic or additive effects (França *et al.*, 2016b). For DBP11, although this and previous studies observed the presence of strain-specific antibodies (Cole-Tobian *et al.*, 2009), strain-transcending antibodies (in particular those targeting the binding pocket) have been described (King *et al.*, 2008; Chen *et al.*, 2016; Wongkidakarn *et al.*, 2016), indicating that a DBP11 vaccine targeting these strain-transcending epitopes may be able to overcome the large genetic diversity of DBP11. Nevertheless, the analyses of antigen combinations clearly indicated that combining DBP11 with other antigens such as one of several RBPs is likely to be beneficial.

The majority of the antigens associated with protection against vivax malaria in this cohort were newly described or understudied, such as EBP, P41, CyRPA, RBP1a, and RBP2b. Many of these proteins were similarly or more strongly associated with protective immunity than antibodies to well-studied vaccine candidate antigens such as MSP3 α , AMA1, MSP1, and CSP (Bennett *et al.*, 2016; Cutts *et al.*, 2014; Stanisic *et al.*, 2013), clearly demonstrating that the repertoire of possible antigenic targets present in the *P. vivax* genome should be further expanded. Interestingly, among the highly-immunogenic proteins expressed in the WGCF system, only two, PVX_122805, a conserved hypothetical protein and PVX_088820, a member of the Pv-fam-a tryptophan-rich antigen family showed substantial association with protection individually, and were regularly included in combinations of 5–15 antigens. This indicates that immunogenicity by itself is a relatively poor predictor of association with protection, and while such proteins may be good markers of exposure, it is less clear whether they would make effective vaccine candidate antigens.

There was a clear hierarchy in the order in which antigens were included into the best antigen-combinations. The top protective antigens were consistently at the top end of all possible random five-way combinations, an observation that is unlikely to be due to chance if all antigens were equally protective when in combinations. The best single antigen EBP followed by PVX_081550 were always present among the most frequently included proteins in higher combinations. Additional proteins common in combinations of three were CyRPA, RBP1a and RBP2b. Apart from RBP2b, these same proteins are also commonly found in four and five antigen-combinations, together with DBP11, P41 and PVX_099930 (RhopH2).

Literature on the little-studied *P. vivax* antigens associated with protection here is at best scarce. We have recently determined that RBP2b binds exclusively to reticulocytes, raising the prospect that RBP2b may be involved in *P. vivax* reticulocyte-specificity (França *et al.*, 2016b). Among the other antigens strongly associated with protection, P41 is a GPI-anchored protein localized on the merozoite surface which forms a heterodimer with P12 (Hostetler *et al.*, 2015). In *P. falciparum*, neither P41 nor P12 homologs are essential for in vitro parasite growth (Tonkin *et al.*, 2013), but both are immunogenic, and antibodies have been associated with clinical protection (Richards *et al.*, 2013; Osier *et al.*, 2014a). The *P. falciparum* homolog of PVX_081550 has recently been identified as StAR-related lipid transfer protein localized on the parasitophorous vacuole (van Ooij *et al.*, 2013). Both the *P. falciparum* homolog and *P. vivax* PVX_081550 proteins are immunogenic (Fan *et al.*, 2013). It is, however, unclear whether antibodies to PVX_081550 interfere with parasite function or are simply elicited by proteins released from the parasitophorous vacuole upon schizont rupture and thus serve as markers of an individual's immune status (França *et al.*, 2016a). Lastly, also in *P.*

falciparum, CyRPA forms a complex with PfRh5 and PfRipr on the merozoite surface. This complex is involved in binding basigin on the erythrocyte surface (Reddy et al., 2015). *P. falciparum* CyRPA seems to not be under immune selection pressure and is highly-conserved, with only a single polymorphism detected across 18 *P. falciparum* strains (Beeson et al., 2016). Antibodies raised against *P. falciparum* CyRPA were nevertheless capable of inhibiting merozoite invasion (Beeson et al., 2016), block binding of CyRPA to Rh5 and Rh5/CyRPA/Ripr complex formation (Chen et al., 2017), and both in vitro and in vivo parasite growth inhibitory activity, more stronger when in combination with PfRh5 (Favuzza et al., 2017). The *P. vivax* CyRPA seems to be highly-reactogenic (França et al., 2016a), suggesting that their function, or at least exposure to the immune system, may differ between the two species.

IgG subclass responses to some *P. vivax* antigens such as RBP1a, DBP11, MSP1 19, and CSP (França et al., 2016b; Tran et al., 2005; Maestre et al., 2010; Yildiz Zeyrek et al., 2011; Zeyrek et al., 2008), as well as several different *P. falciparum* antigens (Stanisic et al., 2015; Ahmed Ismail et al., 2014; Richards et al., 2010; Reiling et al., 2010; Noland et al., 2015; Tongren et al., 2006) have consistently shown that the presence of IgG1 and/or IgG3 in variable ratios is likely to play a role in protection against infection and/or clinical disease. The role of IgG2 and IgG4 antibodies however, remains mostly unclear. IgG2 antibodies have been correlated with lower *P. falciparum* parasitemia (Ahmed Ismail et al., 2014) and risk of infection (Aucan et al., 2000), while IgG4 levels were associated with an enhanced risk of infection and disease (Aucan et al., 2000). Neither showed significant ability to promote opsonic phagocytosis (Osier et al., 2014b), with IgG4 possibly inhibiting this process (Chaudhury et al., 2017). We have previously measured IgG subclass 1, 2, 3 and 4 responses to the 5 RBPs included in this study, showing that IgG1 and IgG3 are the predominant subclasses in this cohort of PNG children (França et al., 2016b). IgG1 to RBP1a and RBP2b showed the strongest association with protection in multivariate models. Interestingly, adults showed substantially higher levels of IgG3 for all antigens (IgG3 being predominant for RBP1a), and substantial levels of IgG2 for some (e.g. RBP2b) but not all antigens. Children showed some early evidence of switching to IgG3 for RBP1a and RBP2-P2 with maturation of immune responses, and increase in age and exposure to malaria parasites (França et al., 2016b).

Little is known about the threshold necessary for antibody levels to switch from being biomarkers of exposure to biomarkers of protection (Stanisic et al., 2015). Large variation in the threshold levels associated with 50% reduction in vivax malaria risk was observed for the present antigen panel. Although this type of analysis cannot differentiate between direct, causal protective effect of antibodies and a statistical association, the observations that many of the antigens most consistently associated with protection in multi-antigen combinations (e.g. PVX_081550, EBP, CyRPA) show both relatively low immunogenicity and low 50% protection threshold levels suggests that for some of the most promising candidate antigens, low antibody levels may be sufficient for protection. It is possible that critical antigens or epitopes have to be weakly immunogenic to avoid acquisition of host immunity. Antigens with little reactivity and associated with acquired immunity at low antibody levels might thus be the most promising for vaccine development. It was, however, not possible to determine in this study whether antibodies to these proteins have better avidity/affinity than some antigens that induce very high antibody levels. One limitation of the dose-response model used in this study is that it only includes one antigen at a time, and thus doesn't account for the complexity of highly-correlated antibody responses.

We focused on 1–3 years old children as early infancy is a critical time in the development of immunity to malaria (Longley et al., 2016). Nevertheless, further studies including older age groups from different transmission settings will be required to confirm the detected hierarchy in antibody responses and their association with protection. To our knowledge, the present study is the largest comprehensive panel of *P. vivax* antigens measured in a well-designed cohort study for identification of associations with malaria risk, and the first one to investigate both the effect of multiple combinations and the threshold antibody levels necessary for protection. Our results identify important targets of naturally-acquired immunity that may contribute to clinical protection and should thus be prioritized for functional studies. These results clearly indicate that examining multiple antigens simultaneously can best correlate with protection, as it might optimally define the breadth of the immune response required for clinical immunity. Taken together, our results suggest that a well-designed, multicomponent *P. vivax* vaccine may be more efficacious than single-component vaccines.

Future research should focus on uncovering the functional role of the unknown and understudied proteins identified in this study, and their potential for vaccines, biomarkers of immunity, or both. The measurement of functionality, e.g. antibodies' capacity to promote opsonic phagocytosis or ability to block binding/invasion to red blood cells will be particularly important (Teo *et al.*, 2016). Although it remains unclear which mechanisms are most important for protection from malaria infection or clinical disease, recent studies with *P. falciparum* suggest that a combination of functional mechanisms may be important for protective immunity (Osier *et al.*, 2014b; Hill *et al.*, 2013; Hill *et al.*, 2016; Chiu *et al.*, 2015; Joos *et al.*, 2010; Murungi *et al.*, 2016). Hence, the presence/levels of functional antibodies might possibly be even better correlates of protective immunity than total IgG antibody levels.

Materials and methods

Study participants and ethical approval

Samples from a longitudinal cohort of young PNG children were used (Lin *et al.*, 2010). Briefly, 264 children aged 1–3 years from an area near Maprik, East Sepik Province, were enrolled from March to September 2006. Children were followed for up to 16 months, with active monitoring of morbidity every two weeks. All PCR-positive *P. vivax* infections were genotyped, allowing the determination of the incidence of genetically distinct blood-stage infections acquired during follow-up (i.e. the molecular force of blood-stage infections, molFOB) (Koepfli *et al.*, 2013). Samples collected at the start of the study from 225 children who completed follow-up were included in the present study. Ethical clearance for this study was obtained from the Medical Research and Advisory Committee of the Ministry of Health in PNG (MRAC 05.19), and the Walter and Eliza Hall Institute (HREC 07/07). Written informed consent was obtained from the parents or guardians of all children participating in the PNG cohort study prior to enrolment.

Antigen selection

A panel of 38 recombinant *P. vivax* antigens was included in this study. The complete list of antigens and their accession numbers can be found in **Supplementary file 1**. Both leading vaccine candidate proteins (i.e. five allelic variants of DBP11, CSP, AMA1 and MSP1), and proteins that are known or predicted to be involved in erythrocyte invasion were included (five different constructs of MSP3 α , MSP9, ARP, GAMA, P12, P41, CyRPA, RBP1a, RBP2a, RBP2b, RBP2cNB [i.e. not containing the binding domain], RBP2-P2, and EBP; **Supplementary file 1**). Additionally, bioinformatics approaches were used to identify novel proteins on the basis of expression profile, signal peptide, putative GPI anchor, and homology to known *P. falciparum* antigens (which were thus likely to be exposed to the immune-system during erythrocyte invasion or in schizonts (Hostetler *et al.*, 2015; Arumugam *et al.*, 2014) (**Supplementary file 1**). These later antigens include both a hypothetical protein thought to be involved in erythrocyte invasion (PVX_081550) and a panel of antigens found to be highly recognized in a screen of plasma from PNG children aged 5–14 years, including RAMA, SERA, RhopH2, AKLP2, CCp5, 2 Pv-fam-a (PVX_088820 and PVX_092995), and hypothetical proteins PVX_080665, PVX_087670, PVX_094350, PVX_114330, and PVX_122085 (Mueller, Takashima and Tsuboi, personal communication).

Antigens were produced in different collaborating laboratories using mostly HEK 293E cells, *E. coli*, or a WGCF expression system as previously described (Hostetler *et al.*, 2015; Gruszczyk *et al.*, 2016; Arumugam *et al.*, 2014). Purification tags included either hexa-his or Cd4 (**Supplementary file 1**). Protein folding has been validated previously by demonstrating that plasma from naturally-exposed populations recognize the native protein, and antibodies to some of them are strongly associated with reduced risk of vivax malaria (Lu *et al.*, 2014; Stanisc *et al.*, 2013; Cole-Tobian *et al.*, 2009; Hostetler *et al.*, 2015; França *et al.*, 2016a; Yadava *et al.*, 2007); by demonstrating that vaccine-induced antibodies raised against the recombinant protein recognize the native protein (Bennett *et al.*, 2016); by showing that the proteins have appropriate biological function through the identification of protein-protein interactions (Hostetler *et al.*, 2015); or by obtaining a crystal structure (Gruszczyk *et al.*, 2016).

Antibody measurement

Purified proteins were conjugated onto Luminex Microplex microspheres (Luminex Corp.) as described elsewhere (*Kellar et al., 2001*). The concentration of each protein used to conjugate 2.5×10^6 beads can be found on [Supplementary file 1](#). Bead array assays to measure total IgG were performed as described (*França et al., 2016a*). The assay was extensively validated (*França et al., 2016a; França et al., 2016b; Dent et al., 2015*) prior to testing samples in singlicate. Samples from Australian donors and a standard curve made of pooled plasma from immune PNG adults (at dilutions ranging from 1:50 to 1:51200) were used as controls on each plate.

Statistical analysis

The dilutions of the immune pool were fitted as plate-specific standard curves using a 5-parameter logistic regression model. For each sample tested, Luminex median fluorescence intensity (MFI) values were interpolated into relative antibody units based on the parameters estimated from the plate's standard curve. Relative antibody units ranged from 1.95×10^{-5} (i.e., equivalent to 1:51200 dilution of the immune pool) to 0.02 (1:50). To account for the background reactivity to the Cd4-tag (*Hostetler et al., 2015*), antibody levels were re-scaled by using linear regression and IgG responses to the Cd4 tag alone (*França et al., 2016a*).

Associations between antibodies and age were assessed using Spearman's rank correlation tests, and differences by infection status using two-tailed unpaired t-test after \log_{10} transformation. To analyze the relationship between IgG levels and prospective risk of *P. vivax* episodes (defined as axillary temperature $\geq 37.5^\circ\text{C}$ or history of fever in preceding 48 hr with a concurrent *P. vivax* parasitemia >500 parasites/ μL), negative binomial generalized estimating equation (GEE) models with exchangeable correlation structure and semi-robust variance estimator were used (*Stanisic et al., 2013; França et al., 2016a; França et al., 2016b*). For this, IgG levels were classified into tertiles and analyses done comparing children with medium and high versus low antibody levels. Children were considered at risk from the first day after the blood sample for active follow-up was taken. The molFOB, representing individual differences in exposure, was calculated as the number of new *P. vivax* blood-stage clones acquired per year-at-risk, and square root transformed for better fit (*Koepfli et al., 2013*). All GEE models were adjusted for seasonal trends, village of residency, age, and individual differences in exposure (molFOB).

Simulated annealing for investigating combinations of antigens

The number of combinations from a panel of 38 antigens is enormous ($2^{38} \sim 2.7 \times 10^{11}$), making investigation of every combination computationally infeasible. In practice, it is possible to investigate all possible combinations of antigens of size up to five, where there are approximately 500,000 combinations (*Osier et al., 2014a*). Investigation of combinations of more than five antigens can be done through efficient exploration of combination space, focusing on the combinations that have the strongest association with protection against clinical malaria.

A simulated annealing algorithm (*Kirkpatrick et al., 1983*) was used to explore the combination space of 38 antigens to identify combinations with optimal potential protective efficacy, defined as the proportional reduction in cases of *P. vivax* clinical malaria comparing children with high versus low antibody levels. The algorithm was implemented with various constraints on the maximum number of antigens in a combination (e.g. no more than 10 antigens allowed in a combination). For each constraint on the maximum number of antigens, the algorithm was repeated 1000 times.

Dose-response relationship

A dose-response model (*White et al., 2011; Chiu et al., 2016*) was used to investigate associations between incidence of clinical malaria and antibody levels. It was assumed that given an individual's antibody level A , the incidence of clinical malaria can be described as:

$$\lambda(A) = \lambda_0 \left(1 - P_{\max} + P_{\max} \frac{1}{1 + \left(\frac{A}{\beta}\right)^\alpha} \right)$$

where: λ_0 = the incidence of clinical malaria in the absence of antibodies; A = an individual's antibody level; P_{\max} = the maximum reduction in incidence due to the antibody under investigation;

α = shape parameter of the dose-response curve; and β = scale parameter of the dose-response curve.

The parameters were estimated by fitting to data on the incidence of clinical malaria within each time period. In interval j of duration T_j the probability that an episode of clinical malaria occurs is:

$$P(A_j) = 1 - e^{-\lambda(A_j)T_j}$$

The likelihood that the dose-response function given the data is:

$$L = \prod_j P(A_j)^{I_j} (1 - P(A_j))^{1 - I_j}$$

where $I_j = 1$ for an individual who experienced a clinical episode in interval j ; $I_j = 0$ if there was no observed episode during the interval.

The model was fitted to the data in a Bayesian framework using Markov Chain Monte Carlo (MCMC) methods. Parameters were assumed to have uniform prior distributions (*White et al., 2011; Chiu et al., 2016*).

Acknowledgements

We thank all patients and their families for participating in this study. We gratefully acknowledge the large Papua New Guinean team for its help in conducting the fieldwork, Ms Sumana Sharma for her help in expressing proteins, and Dr. Rhea Longley for her thoughtful suggestions.

Additional information

Funding

Funder	Grant reference number	Author
University of Melbourne	Melbourne International Postgraduate Scholarship	Camila Tenorio França Wen-Qiang He
National Health and Medical Research Council	1092789	Alan F Cowman
National Health and Medical Research Council	Program Grant 1092789	Ivo Mueller Alan F Cowman
Japan Society for the Promotion of Science	JP26253026	Takafumi Tsuboi
Japan Society for the Promotion of Science	JP15H05276	Takafumi Tsuboi
Japan Society for the Promotion of Science	JP16K15266	Takafumi Tsuboi
Australian Research Council	Australian Research Council Future Fellowship	Wai-Hong Tham
National Institute of Allergy and Infectious Diseases	Intramural Research Program	Rick M Fairhurst
National Institutes of Health	AI063135	Rick M Fairhurst
Wellcome	098051	Julian C Rayner
Medical Research Council	MR/J002283/1	Julian C Rayner
Medical Research Council	MR/L012170/1	Julian C Rayner
National Institutes of Health	U19AI089686	Ivo Mueller
National Health and Medical Research Council	1021544	Ivo Mueller
Malaria Eradication Scientific Alliance		Ivo Mueller

National Health and Medical Research Council	Independent Research Institute Infrastructure Support Scheme	Ivo Mueller
National Health and Medical Research Council	Senior Research Fellowship 1043345	Ivo Mueller

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of Health and Human Services, Department of the Army, the Department of Defense, nor the U.S. Government.

Author contributions

Camila Tenorio França, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing—original draft; Michael T White, Formal analysis, Visualization, Methodology, Writing—original draft; Wen-Qiang He, Investigation, Writing—review and editing; Jessica B Hostetler, Jakub Gruszczyk, Anjali Yadava, Mary R Galinski, Julie Healer, Chetan Chitnis, Eizo Takashima, Resources, Writing—review and editing; Jessica Brewster, Validation, Investigation; Gabriel Frato, Indu Malhotra, Christele Huon, Enmoore Lin, Benson Kiniboro, Resources, Methodology; Peter Siba, Conceptualization, Resources, Funding acquisition; Alan F Cowman, Takafumi Tsuboi, Wai-Hong Tham, Rick M Fairhurst, Julian C Rayner, Resources, Funding acquisition, Writing—review and editing; Christopher L King, Conceptualization, Resources, Funding acquisition, Methodology, Writing—review and editing; Ivo Mueller, Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Methodology, Project administration, Writing—review and editing

Author ORCIDs

Camila Tenorio França  <http://orcid.org/0000-0001-5885-4410>

Jakub Gruszczyk  <http://orcid.org/0000-0003-4536-2964>

Anjali Yadava  <https://orcid.org/0000-0002-6751-954X>

Alan F Cowman  <http://orcid.org/0000-0001-5145-9004>

Ivo Mueller  <http://orcid.org/0000-0001-6554-6889>

Ethics

Human subjects: Ethical clearance for this study was obtained from the Medical Research and Advisory Committee of the Ministry of Health in PNG (MRAC 05.19), and the Walter and Eliza Hall Institute (HREC 07/07). Written informed consent was obtained from the parents or guardians of all children participating in the PNG cohort study prior to enrollment.

Decision letter and Author response

Decision letter <https://doi.org/10.7554/eLife.28673.016>

Author response <https://doi.org/10.7554/eLife.28673.017>

Additional files

Supplementary files

- Supplementary file 1. *P. vivax* antigens included in this study. Conc = concentration; HEK293E = human embryonic kidney 293E cells; WGCF = wheat germ cell-free. *Cd4-tagged proteins. Cd4 alone was conjugated to Luminex beads (2 µg/ml per 2.5×10^6 beads) and tested in all samples as a control for background reactivity.
DOI: <https://doi.org/10.7554/eLife.28673.014>

- Transparent reporting form

DOI: <https://doi.org/10.7554/eLife.28673.015>

References

- Achtman AH**, Bull PC, Stephens R, Langhorne J. 2005. Longevity of the immune response and memory to blood-stage malaria infection. *Current Topics in Microbiology and Immunology* **297**:71–102. DOI: https://doi.org/10.1007/3-540-29967-X_3, PMID: 16265903
- Agandji ST**, Lell B, Fernandes JF, Abossolo BP, Methogo BG, Kabwende AL, Adegnika AA, Mordmüller B, Issifou S, Kreamsner PG, Sacarlal J, Aide P, Lanasma M, Aponte JJ, Machevo S, Acacio S, Bulo H, Sigauque B, Macete E, Alonso P, et al. 2012. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. *The New England journal of medicine* **367**:2284–2295. DOI: <https://doi.org/10.1056/NEJMoa1208394>, PMID: 23136909
- Ahmed Ismail H**, Tijani MK, Langer C, Reiling L, White MT, Beeson JG, Wahlgren M, Nwuba R, Persson KE. 2014. Subclass responses and their half-lives for antibodies against EBA175 and PfRh2 in naturally acquired immunity against *Plasmodium falciparum* malaria. *Malaria Journal* **13**:425. DOI: <https://doi.org/10.1186/1475-2875-13-425>, PMID: 25373511
- Alves E**, Salman AM, Leoratti F, Lopez-Camacho C, Viveros-Sandoval ME, Lall A, El-Turabi A, Bachmann MF, Hill AV, Janse CJ, Khan SM, Reyes-Sandoval A. 2017. Evaluation of plasmodium vivax cell-traversal protein for ookinetes and sporozoites as a preerythrocytic P. vivax vaccine. *Clinical and Vaccine Immunology* **24**:e00501-16. DOI: <https://doi.org/10.1128/CVI.00501-16>, PMID: 28179403
- Arumugam TU**, Ito D, Takashima E, Tachibana M, Ishino T, Torii M, Tsuboi T. 2014. Application of wheat germ cell-free protein expression system for novel malaria vaccine candidate discovery. *Expert Review of Vaccines* **13**:75–85. DOI: <https://doi.org/10.1586/14760584.2014.861747>, PMID: 24308585
- Aucan C**, Traoré Y, Tall F, Nacro B, Traoré-Leroux T, Fumoux F, Rihet P. 2000. High immunoglobulin G2 (IgG2) and low IgG4 levels are associated with human resistance to *Plasmodium falciparum* malaria. *Infection and Immunity* **68**:1252–1258. DOI: <https://doi.org/10.1128/IAI.68.3.1252-1258.2000>, PMID: 10678934
- Bauza K**, Malinauskas T, Pfander C, Anar B, Jones EY, Billker O, Hill AV, Reyes-Sandoval A. 2014. Efficacy of a *Plasmodium vivax* malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic *Plasmodium berghei* parasites. *Infection and Immunity* **82**:1277–1286. DOI: <https://doi.org/10.1128/IAI.01187-13>, PMID: 24379295
- Beeson JG**, Drew DR, Boyle MJ, Feng G, Fowkes FJ, Richards JS. 2016. Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria. *FEMS Microbiology Reviews* **40**:343–372. DOI: <https://doi.org/10.1093/femsre/fuw001>, PMID: 26833236
- Bennett JW**, Yadava A, Tosh D, Sattabongkot J, Komisar J, Ware LA, McCarthy WF, Cowden JJ, Regules J, Spring MD, Paolino K, Hartzell JD, Cummings JF, Richie TL, Lumsden J, Kamau E, Murphy J, Lee C, Parekh F, Birkett A, et al. 2016. Phase 1/2a Trial of *Plasmodium vivax* Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy. *PLOS Neglected Tropical Diseases* **10**:e0004423. DOI: <https://doi.org/10.1371/journal.pntd.0004423>, PMID: 26919472
- Bousema T**, Okell L, Felger I, Drakeley C. 2014. Asymptomatic malaria infections: detectability, transmissibility and public health relevance. *Nature Reviews Microbiology* **12**:833–840. DOI: <https://doi.org/10.1038/nrmicro3364>, PMID: 25329408
- Bozdech Z**, Mok S, Hu G, Imwong M, Jaidee A, Russell B, Ginsburg H, Nosten F, Day NP, White NJ, Carlton JM, Preiser PR. 2008. The transcriptome of *Plasmodium vivax* reveals divergence and diversity of transcriptional regulation in malaria parasites. *PNAS* **105**:16290–16295. DOI: <https://doi.org/10.1073/pnas.0807404105>, PMID: 18852452
- Carlton JM**, Adams JH, Silva JC, Bidwell SL, Lorenzi H, Caler E, Crabtree J, Angiuoli SV, Merino EF, Amedeo P, Cheng Q, Coulson RM, Crabb BS, Del Portillo HA, Essien K, Feldblyum TV, Fernandez-Becerra C, Gilson PR, Gueye AH, Guo X, et al. 2008. Comparative genomics of the neglected human malaria parasite *Plasmodium vivax*. *Nature* **455**:757–763. DOI: <https://doi.org/10.1038/nature07327>, PMID: 18843361
- Chaudhury S**, Regules JA, Darko CA, Dutta S, Wallqvist A, Waters NC, Jongert E, Lemiale F, Bergmann-Leitner ES. 2017. Delayed fractional dose regimen of the RTS,S/AS01 malaria vaccine candidate enhances an IgG4 response that inhibits serum opsonophagocytosis. *Scientific Reports* **7**:7998. DOI: <https://doi.org/10.1038/s41598-017-08526-5>, PMID: 28801554
- Chen E**, Salinas ND, Huang Y, Ntumngia F, Plasencia MD, Gross ML, Adams JH, Tolia NH. 2016. Broadly neutralizing epitopes in the *Plasmodium vivax* vaccine candidate Duffy Binding Protein. *PNAS* **113**:6277–6282. DOI: <https://doi.org/10.1073/pnas.1600488113>, PMID: 27194724
- Chen JH**, Jung JW, Wang Y, Ha KS, Lu F, Lim CS, Takeo S, Tsuboi T, Han ET. 2010. Immunoproteomics profiling of blood stage *Plasmodium vivax* infection by high-throughput screening assays. *Journal of Proteome Research* **9**:6479–6489. DOI: <https://doi.org/10.1021/pr100705g>, PMID: 20949973
- Chen L**, Xu Y, Wong W, Thompson JK, Healer J, Goddard-Borger ED, Lawrence MC, Cowman AF. 2017. Structural basis for inhibition of erythrocyte invasion by antibodies to *Plasmodium falciparum* protein CyRPA. *eLife* **6**:e21347. DOI: <https://doi.org/10.7554/eLife.21347>, PMID: 28195530
- Cheng Q**, Cunningham J, Gatton ML. 2015. Systematic review of sub-microscopic P. vivax infections: prevalence and determining factors. *PLoS Neglected Tropical Diseases* **9**:e3413. DOI: <https://doi.org/10.1371/journal.pntd.0003413>, PMID: 25569135
- Chia WN**, Goh YS, Rénia L. 2014. Novel approaches to identify protective malaria vaccine candidates. *Frontiers in Microbiology* **5**:586. DOI: <https://doi.org/10.3389/fmicb.2014.00586>, PMID: 25452745
- Chiu CY**, Hodder AN, Lin CS, Hill DL, Li Wai Suen CS, Schofield L, Siba PM, Mueller I, Cowman AF, Hansen DS. 2015. Antibodies to the *Plasmodium falciparum* proteins MSPDBL1 and MSPDBL2 opsonize merozoites, inhibit

- parasite growth, and predict protection from clinical malaria. *Journal of Infectious Diseases* **212**:406–415. DOI: <https://doi.org/10.1093/infdis/jiv057>, PMID: 25646353
- Chiu CY**, White MT, Healer J, Thompson JK, Siba PM, Mueller I, Cowman AF, Hansen DS. 2016. Different regions of *Plasmodium falciparum* erythrocyte-binding antigen 175 induce antibody responses to infection of varied efficacy. *Journal of Infectious Diseases* **214**:96–104. DOI: <https://doi.org/10.1093/infdis/jiw119>, PMID: 27020092
- Cole-Tobian JL**, Michon P, Biasor M, Richards JS, Beeson JG, Mueller I, King CL. 2009. Strain-specific duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous *Plasmodium vivax* strains in Papua New Guinean children. *Infection and Immunity* **77**:4009–4017. DOI: <https://doi.org/10.1128/IAI.00158-09>, PMID: 19564376
- Cutts JC**, Powell R, Agius PA, Beeson JG, Simpson JA, Fowkes FJ. 2014. Immunological markers of *Plasmodium vivax* exposure and immunity: a systematic review and meta-analysis. *BMC Medicine* **12**:150. DOI: <https://doi.org/10.1186/s12916-014-0150-1>, PMID: 25199532
- Dent AE**, Malhotra I, Wang X, Babineau D, Yeo KT, Anderson T, Kimmel RJ, Angov E, Lanar DE, Narum D, Dutta S, Richards J, Beeson JG, Crabb BS, Cowman AF, Horii T, Muchiri E, Mungai PL, King CL, Kazura JW. 2015. Contrasting patterns of serologic and functional antibody dynamics to *Plasmodium falciparum* antigens in a Kenyan birth cohort. *Clinical and Vaccine Immunology* **23**:104–116. DOI: <https://doi.org/10.1128/CVI.00452-15>, PMID: 26656119
- Fan YT**, Wang Y, Ju C, Zhang T, Xu B, Hu W, Chen JH. 2013. Systematic analysis of natural antibody responses to *P. falciparum* merozoite antigens by protein arrays. *Journal of Proteomics* **78**:148–158. DOI: <https://doi.org/10.1016/j.jprot.2012.11.020>, PMID: 23201113
- Favuzza P**, Guffart E, Tamborrini M, Scherer B, Dreyer AM, Rufer AC, Erny J, Hoernschemeyer J, Thoma R, Schmid G, Gsell B, Lamelas A, Benz J, Joseph C, Matile H, Pluschke G, Rudolph MG. 2017. Structure of the malaria vaccine candidate antigen CyRPA and its complex with a parasite invasion inhibitory antibody. *eLife* **6**:e20383. DOI: <https://doi.org/10.7554/eLife.20383>, PMID: 28195038
- Finney OC**, Danziger SA, Molina DM, Vignali M, Takagi A, Ji M, Stanisic DI, Siba PM, Liang X, Aitchison JD, Mueller I, Gardner MJ, Wang R. 2014. Predicting antidisease immunity using proteome arrays and sera from children naturally exposed to malaria. *Molecular & Cellular Proteomics* **13**:2646–2660. DOI: <https://doi.org/10.1074/mcp.M113.036632>, PMID: 25023128
- França CT**, He WQ, Gruszczyk J, Lim NT, Lin E, Kiniboro B, Siba PM, Tham WH, Mueller I. 2016b. *Plasmodium vivax* Reticulocyte Binding Proteins Are Key Targets of Naturally Acquired Immunity in Young Papua New Guinean Children. *PLOS Neglected Tropical Diseases* **10**:e0005014. DOI: <https://doi.org/10.1371/journal.pntd.0005014>, PMID: 27677183
- França CT**, Hostetler JB, Sharma S, White MT, Lin E, Kiniboro B, Waltmann A, Darcy AW, Li Wai Suen CS, Siba P, King CL, Rayner JC, Fairhurst RM, Mueller I. 2016a. An antibody screen of a *Plasmodium vivax* antigen library identifies novel merozoite proteins associated with clinical protection. *PLOS Neglected Tropical Diseases* **10**:e0004639. DOI: <https://doi.org/10.1371/journal.pntd.0004639>, PMID: 27182597
- Gruszczyk J**, Lim NT, Arnott A, He WQ, Nguiragool W, Roobsoong W, Mok YF, Murphy JM, Smith KR, Lee S, Bahlo M, Mueller I, Barry AE, Tham WH. 2016. Structurally conserved erythrocyte-binding domain in *Plasmodium* provides a versatile scaffold for alternate receptor engagement. *PNAS* **113**:E191–E200. DOI: <https://doi.org/10.1073/pnas.1516512113>, PMID: 26715754
- Halbroth BR**, Draper SJ. 2015. Recent developments in malaria vaccinology. *Advances in parasitology* **88**:1–49. DOI: <https://doi.org/10.1016/bs.apar.2015.03.001>, PMID: 25911364
- Hill DL**, Eriksson EM, Li Wai Suen CS, Chiu CY, Ryg-Cornejo V, Robinson LJ, Siba PM, Mueller I, Hansen DS, Schofield L. 2013. Opsonising antibodies to *P. falciparum* merozoites associated with immunity to clinical malaria. *PLoS One* **8**:e74627. DOI: <https://doi.org/10.1371/journal.pone.0074627>, PMID: 24040299
- Hill DL**, Wilson DW, Sampaio NG, Eriksson EM, Ryg-Cornejo V, Harrison GL, Uboldi AD, Robinson LJ, Beeson JG, Siba P, Cowman AF, Hansen DS, Mueller I, Schofield L. 2016. Merozoite Antigens of *Plasmodium falciparum* Elicit Strain-Transcending Opsonizing Immunity. *Infection and Immunity* **84**:2175–2184. DOI: <https://doi.org/10.1128/IAI.00145-16>, PMID: 27185785
- Hostetler JB**, Sharma S, Bartholdson SJ, Wright GJ, Fairhurst RM, Rayner JC. 2015. A Library of *Plasmodium vivax* Recombinant Merozoite Proteins Reveals New Vaccine Candidates and Protein-Protein Interactions. *PLOS Neglected Tropical Diseases* **9**:e0004264. DOI: <https://doi.org/10.1371/journal.pntd.0004264>, PMID: 26701602
- Joos C**, Marrama L, Polson HE, Corre S, Diatta AM, Diouf B, Trape JF, Tall A, Longacre S, Perraut R. 2010. Clinical protection from falciparum malaria correlates with neutrophil respiratory bursts induced by merozoites opsonized with human serum antibodies. *PLoS One* **5**:e9871. DOI: <https://doi.org/10.1371/journal.pone.0009871>, PMID: 20360847
- Kellar KL**, Kalwar RR, Dubois KA, Crouse D, Chafin WD, Kane BE. 2001. Multiplexed fluorescent bead-based immunoassays for quantitation of human cytokines in serum and culture supernatants. *Cytometry* **45**:27–36. DOI: [https://doi.org/10.1002/1097-0320\(20010901\)45:1<27::AID-CYTO1141>3.0.CO;2-I](https://doi.org/10.1002/1097-0320(20010901)45:1<27::AID-CYTO1141>3.0.CO;2-I), PMID: 11598944
- King CL**, Michon P, Shakri AR, Marcotty A, Stanisic D, Zimmerman PA, Cole-Tobian JL, Mueller I, Chitnis CE. 2008. Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage *Plasmodium vivax* infection. *PNAS* **105**:8363–8368. DOI: <https://doi.org/10.1073/pnas.0800371105>, PMID: 18523022
- Kirkpatrick S**, Gelatt CD, Vecchi MP. 1983. Optimization by simulated annealing. *Science* **220**:671–680. DOI: <https://doi.org/10.1126/science.220.4598.671>, PMID: 17813860

- Koepfli C**, Colborn KL, Kiniboro B, Lin E, Speed TP, Siba PM, Felger I, Mueller I. 2013. A high force of plasmodium vivax blood-stage infection drives the rapid acquisition of immunity in papua new guinean children. *PLoS Neglected Tropical Diseases* **7**:e2403. DOI: <https://doi.org/10.1371/journal.pntd.0002403>, PMID: 24040428
- Lin E**, Kiniboro B, Gray L, Dobbie S, Robinson L, Laumaea A, Schöpflin S, Stanisic D, Betuela I, Blood-Zikursh M, Siba P, Felger I, Schofield L, Zimmerman P, Mueller I. 2010. Differential patterns of infection and disease with *P. falciparum* and *P. vivax* in young Papua New Guinean children. *PLoS One* **5**:e9047. DOI: <https://doi.org/10.1371/journal.pone.0009047>, PMID: 20140220
- Longley RJ**, Reyes-Sandoval A, Montoya-Díaz E, Dunachie S, Kumpitak C, Nguitragool W, Mueller I, Sattabongkot J. 2015. Acquisition and longevity of antibodies to Plasmodium vivax preerythrocytic antigens in Western Thailand. *Clinical and Vaccine Immunology* **23**:117–124. DOI: <https://doi.org/10.1128/CVI.00501-15>, PMID: 26656115
- Longley RJ**, Sattabongkot J, Mueller I. 2016. Insights into the naturally acquired immune response to Plasmodium vivax malaria. *Parasitology* **143**:154–170. DOI: <https://doi.org/10.1017/S0031182015000670>, PMID: 26864134
- Lu F**, Li J, Wang B, Cheng Y, Kong DH, Cui L, Ha KS, Sattabongkot J, Tsuboi T, Han ET. 2014. Profiling the humoral immune responses to Plasmodium vivax infection and identification of candidate immunogenic rhoptry-associated membrane antigen (RAMA). *Journal of Proteomics* **102**:66–82. DOI: <https://doi.org/10.1016/j.jprot.2014.02.029>, PMID: 24607491
- Maestre A**, Muskus C, Duque V, Agudelo O, Liu P, Takagi A, Ntumngia FB, Adams JH, Sim KL, Hoffman SL, Corradin G, Velez ID, Wang R. 2010. Acquired antibody responses against Plasmodium vivax infection vary with host genotype for duffy antigen receptor for chemokines (DARC). *PLoS One* **5**:e11437. DOI: <https://doi.org/10.1371/journal.pone.0011437>, PMID: 20664684
- malERA Consultative Group on Vaccines**. 2011. A research agenda for malaria eradication: vaccines. *PLoS Medicine* **8**:e1000398. DOI: <https://doi.org/10.1371/journal.pmed.1000398>, PMID: 21311586
- Mueller I**, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, del Portillo HA. 2009. Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. *The Lancet Infectious Diseases* **9**:555–566. DOI: [https://doi.org/10.1016/S1473-3099\(09\)70177-X](https://doi.org/10.1016/S1473-3099(09)70177-X), PMID: 19695492
- Mueller I**, Schoepflin S, Smith TA, Benton KL, Bretscher MT, Lin E, Kiniboro B, Zimmerman PA, Speed TP, Siba P, Felger I. 2012. Force of infection is key to understanding the epidemiology of Plasmodium falciparum malaria in Papua New Guinean children. *PNAS* **109**:10030–10035. DOI: <https://doi.org/10.1073/pnas.1200841109>, PMID: 22665809
- Mueller I**, Shakri AR, Chitnis CE. 2015. Development of vaccines for Plasmodium vivax malaria. *Vaccine* **33**:7489–7495. DOI: <https://doi.org/10.1016/j.vaccine.2015.09.060>, PMID: 26428453
- Murungi LM**, Sondén K, Llewellyn D, Rono J, Guleid F, Williams AR, Ogada E, Thairu A, Färnert A, Marsh K, Draper SJ, Osier FH. 2016. Targets and mechanisms associated with protection from severe Plasmodium falciparum malaria in kenyan children. *Infection and Immunity* **84**:950–963. DOI: <https://doi.org/10.1128/IAI.01120-15>, PMID: 26787721
- Noland GS**, Jansen P, Vulule JM, Park GS, Ondigo BN, Kazura JW, Moormann AM, John CC. 2015. Effect of transmission intensity and age on subclass antibody responses to Plasmodium falciparum pre-erythrocytic and blood-stage antigens. *Acta Tropica* **142**:47–56. DOI: <https://doi.org/10.1016/j.actatropica.2014.10.011>, PMID: 25446174
- Osier FH**, Feng G, Boyle MJ, Langer C, Zhou J, Richards JS, McCallum FJ, Reiling L, Jaworowski A, Anders RF, Marsh K, Beeson JG. 2014b. Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria. *BMC Medicine* **12**:108. DOI: <https://doi.org/10.1186/1741-7015-12-108>, PMID: 24980799
- Osier FH**, Mackinnon MJ, Crosnier C, Fegan G, Kamuyu G, Wanaguru M, Ogada E, McDade B, Rayner JC, Wright GJ, Marsh K. 2014a. New antigens for a multicomponent blood-stage malaria vaccine. *Science Translational Medicine* **6**:247ra102. DOI: <https://doi.org/10.1126/scitranslmed.3008705>, PMID: 25080477
- Phimpraphi W**, Paul RE, Yimsamran S, Puangsa-art S, Thanyavanich N, Maneeboonyang W, Prommongkol S, Sornklom S, Chaimungkun W, Chavez IF, Blanc H, Looareesuwan S, Sakuntabhai A, Singhasivanon P. 2008. Longitudinal study of Plasmodium falciparum and Plasmodium vivax in a Karen population in Thailand. *Malaria Journal* **7**:99. DOI: <https://doi.org/10.1186/1475-2875-7-99>, PMID: 18518964
- Rayner JC**, Corredor V, Feldman D, Ingravallo P, Iderabdullah F, Galinski MR, Barnwell JW. 2002. Extensive polymorphism in the plasmodium vivax merozoite surface coat protein MSP-3alpha is limited to specific domains. *Parasitology* **125**:393–405. DOI: <https://doi.org/10.1017/S0031182002002317>, PMID: 12458823
- Reddy KS**, Amlabu E, Pandey AK, Mitra P, Chauhan VS, Gaur D. 2015. Multiprotein complex between the GPI-anchored CyRPA with PfrH5 and PfrIpr is crucial for Plasmodium falciparum erythrocyte invasion. *PNAS* **112**:1179–1184. DOI: <https://doi.org/10.1073/pnas.1415466112>, PMID: 25583518
- Reiling L**, Richards JS, Fowkes FJ, Barry AE, Triglia T, Chokejindachai W, Michon P, Tavul L, Siba PM, Cowman AF, Mueller I, Beeson JG. 2010. Evidence that the erythrocyte invasion ligand PfrH2 is a target of protective immunity against Plasmodium falciparum malaria. *The Journal of Immunology* **185**:6157–6167. DOI: <https://doi.org/10.4049/jimmunol.1001555>, PMID: 20962255
- Richards JS**, Arumugam TU, Reiling L, Healer J, Hodder AN, Fowkes FJ, Cross N, Langer C, Takeo S, Uboldi AD, Thompson JK, Gilson PR, Coppel RL, Siba PM, King CL, Torii M, Chitnis CE, Narum DL, Mueller I, Crabb BS, et al. 2013. Identification and prioritization of merozoite antigens as targets of protective human immunity to

- Plasmodium falciparum malaria for vaccine and biomarker development. *The Journal of Immunology* **191**:795–809. DOI: <https://doi.org/10.4049/jimmunol.1300778>, PMID: 23776179
- Richards JS**, Stanicic DI, Fowkes FJ, Tavul L, Dabod E, Thompson JK, Kumar S, Chitnis CE, Narum DL, Michon P, Siba PM, Cowman AF, Mueller I, Beeson JG. 2010. Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia. *Clinical Infectious Diseases* **51**:e50–e60. DOI: <https://doi.org/10.1086/656413>, PMID: 20843207
- Robinson LJ**, Wampfler R, Betuela I, Karl S, White MT, Li Wai Suen CS, Hofmann NE, Kinboro B, Waltmann A, Brewster J, Lorry L, Tarongka N, Samol L, Silkey M, Bassat Q, Siba PM, Schofield L, Felger I, Mueller I. 2015. Strategies for understanding and reducing the Plasmodium vivax and Plasmodium ovale hypnozoite reservoir in Papua New Guinean children: a randomised placebo-controlled trial and mathematical model. *PLOS Medicine* **12**:e1001891. DOI: <https://doi.org/10.1371/journal.pmed.1001891>, PMID: 26505753
- RTS,S Clinical Trials Partnership**. 2014. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. *PLoS Medicine* **11**:e1001685. DOI: <https://doi.org/10.1371/journal.pmed.1001685>, PMID: 25072396
- Salman AM**, Montoya-Díaz E, West H, Lall A, Atcheson E, Lopez-Camacho C, Ramesar J, Bauza K, Collins KA, Brod F, Reis F, Pappas L, González-Cerón L, Janse CJ, Hill AVS, Khan SM, Reyes-Sandoval A. 2017. Rational development of a protective P. vivax vaccine evaluated with transgenic rodent parasite challenge models. *Scientific Reports* **7**:46482. DOI: <https://doi.org/10.1038/srep46482>, PMID: 28417968
- Stanicic DI**, Fowkes FJ, Koinari M, Javati S, Lin E, Kiniboro B, Richards JS, Robinson LJ, Schofield L, Kazura JW, King CL, Zimmerman P, Felger I, Siba PM, Mueller I, Beeson JG. 2015. Acquisition of antibodies against Plasmodium falciparum merozoites and malaria immunity in young children and the influence of age, force of infection, and magnitude of response. *Infection and Immunity* **83**:646–660. DOI: <https://doi.org/10.1128/IAI.02398-14>, PMID: 25422270
- Stanicic DI**, Javati S, Kiniboro B, Lin E, Jiang J, Singh B, Meyer EV, Siba P, Koepfli C, Felger I, Galinski MR, Mueller I. 2013. Naturally acquired immune responses to P. vivax merozoite surface protein 3 α and merozoite surface protein 9 are associated with reduced risk of P. vivax malaria in young Papua New Guinean children. *PLoS Neglected Tropical Diseases* **7**:e2498. DOI: <https://doi.org/10.1371/journal.pntd.0002498>, PMID: 24244763
- Tanner M**, Greenwood B, Whitty CJ, Ansah EK, Price RN, Dondorp AM, von Seidlein L, Baird JK, Beeson JG, Fowkes FJ, Hemingway J, Marsh K, Osier F. 2015. Malaria eradication and elimination: views on how to translate a vision into reality. *BMC Medicine* **13**:167. DOI: <https://doi.org/10.1186/s12916-015-0384-6>, PMID: 26208740
- Teo A**, Feng G, Brown GV, Beeson JG, Rogerson SJ. 2016. Functional Antibodies and Protection against Blood-stage Malaria. *Trends in Parasitology* **32**:887–898. DOI: <https://doi.org/10.1016/j.pt.2016.07.003>, PMID: 27546781
- Tongren JE**, Drakeley CJ, McDonald SL, Reyburn HG, Manjurano A, Nkya WM, Lemnge MM, Gowda CD, Todd JE, Corran PH, Riley EM. 2006. Target antigen, age, and duration of antigen exposure independently regulate immunoglobulin G subclass switching in malaria. *Infection and Immunity* **74**:257–264. DOI: <https://doi.org/10.1128/IAI.74.1.257-264.2006>, PMID: 16368979
- Tonkin ML**, Arredondo SA, Loveless BC, Serpa JJ, Makepeace KA, Sundar N, Petrotchenko EV, Miller LH, Grigg ME, Boulanger MJ. 2013. Structural and biochemical characterization of Plasmodium falciparum 12 (Pf12) reveals a unique interdomain organization and the potential for an antiparallel arrangement with Pf41. *Journal of Biological Chemistry* **288**:12805–12817. DOI: <https://doi.org/10.1074/jbc.M113.455667>, PMID: 23511632
- Tran TM**, Oliveira-Ferreira J, Moreno A, Santos F, Yazdani SS, Chitnis CE, Altman JD, Meyer EV, Barnwell JW, Galinski MR. 2005. Comparison of IgG reactivities to Plasmodium vivax merozoite invasion antigens in a Brazilian Amazon population. *The American Journal of Tropical Medicine and Hygiene* **73**:244–255. DOI: <https://doi.org/10.4269/ajtmh.2005.73.244>, PMID: 16103583
- Tsuboi T**, Takeo S, Arumugam TU, Otsuki H, Torii M. 2010. The wheat germ cell-free protein synthesis system: a key tool for novel malaria vaccine candidate discovery. *Acta Tropica* **114**:171–176. DOI: <https://doi.org/10.1016/j.actatropica.2009.10.024>, PMID: 19913490
- van Ooij C**, Withers-Martinez C, Ringel A, Cockcroft S, Haldar K, Blackman MJ. 2013. Identification of a Plasmodium falciparum phospholipid transfer protein. *Journal of Biological Chemistry* **288**:31971–31983. DOI: <https://doi.org/10.1074/jbc.M113.474189>, PMID: 24043620
- White MT**, Griffin JT, Riley EM, Drakeley CJ, Moorman AM, Sumba PO, Kazura JW, Ghani AC, John CC. 2011. Efficacy model for antibody-mediated pre-erythrocytic malaria vaccines. *Proceedings. Biological sciences* **278**:1298–1305. DOI: <https://doi.org/10.1098/rspb.2010.1697>, PMID: 20943696
- WHO**. 2014. *World Malaria Report 2014* Geneva, Switzerland: World Health Organization.
- Wipasa J**, Suphavitai C, Okell LC, Cook J, Corran PH, Thaikla K, Liwarsaree W, Riley EM, Hafalla JC. 2010. Long-lived antibody and B Cell memory responses to the human malaria parasites, Plasmodium falciparum and Plasmodium vivax. *PLoS Pathogens* **6**:e1000770. DOI: <https://doi.org/10.1371/journal.ppat.1000770>, PMID: 20174609
- Wongkidakarn S**, McHenry AM, Sattabongkot J, Adams JH, Chootong P. 2016. Strain-Transcending Inhibitory Antibodies against Homologous and Heterologous Strains of Duffy Binding Protein region II. *PLoS One* **11**:e0154577. DOI: <https://doi.org/10.1371/journal.pone.0154577>, PMID: 27145131
- Yadava A**, Sattabongkot J, Washington MA, Ware LA, Majam V, Zheng H, Kumar S, Ockenhouse CF. 2007. A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that

recognize both VK210 and VK247 sporozoites. *Infection and Immunity* **75**:1177–1185. DOI: <https://doi.org/10.1128/IAI.01667-06>, PMID: 17158893

Yildiz Zeyrek F, Palacpac N, Yuksel F, Yagi M, Honjo K, Fujita Y, Arisue N, Takeo S, Tanabe K, Horii T, Tsuboi T, Ishii KJ, Coban C. 2011. Serologic markers in relation to parasite exposure history help to estimate transmission dynamics of *Plasmodium vivax*. *PLoS One* **6**:e28126. DOI: <https://doi.org/10.1371/journal.pone.0028126>, PMID: 22140521

Zeyrek FY, Babaoglu A, Demirel S, Erdogan DD, Ak M, Korkmaz M, Coban C. 2008. Analysis of naturally acquired antibody responses to the 19-kd C-terminal region of merozoite surface protein-1 of *Plasmodium vivax* from individuals in Sanliurfa, Turkey. *The American journal of tropical medicine and hygiene* **78**:729–732. PMID: 18458304